Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.65 |
| ▸ | AR | P10275 | 3/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12558847 | 1.00 | PGR (0.65) | PGRARNR3C1LMNAABCC4 | |
| SCHEMBL12558807 | 0.90 | PGR (0.62) | PGRARNR3C1LMNAABCC4 | |
| SCHEMBL13146528 | 0.90 | PGR (0.62) | PGRARNR3C1LMNAABCC4 | |
| SCHEMBL12558787 | 0.85 | PGR (0.56) | PGRARNR3C1LMNAABCC4 | |
| SCHEMBL13046014 | 0.81 | PGR (0.68) | PGRARNR3C1LMNAABCC4 | |
| SCHEMBL14981310 | 0.81 | PGR (0.88) | PGRARNR3C1LMNAABCC4 | |
| SCHEMBL13139288 | 0.80 | PGR (0.65) | PGRARNR3C1LMNAABCC4 | |
| SCHEMBL13093755 | 0.80 | PGR (0.65) | PGRARNR3C1LMNAABCC4 | |
| SCHEMBL14256372 | 0.80 | PGR (0.80) | PGRARNR3C1LMNAABCC4 | |
| SCHEMBL13146516 | 0.80 | PGR (0.57) | PGRARNR3C1LMNAABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334375-B2 | Methods for the preparation of drospirenone | EVESTRA, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20100261896-A1 | METHODS FOR THE PREPARATION OF DROSPIRENONE | EVESTRA, INC. | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261896-A1 | METHODS FOR THE PREPARATION OF DROSPIRENONE | CYP17A1, CYP11A1, DHCR7 | PGR 357/4885AR 211/4885NR3C1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.